UK medical cannabis registry: an updated clinical outcomes analysis of patients with post-traumatic stress disorder

Cannabis-based medicinal products (CBMPs) are a potential treatment for post-traumatic stress disorder (PTSD), but their long-term efficacy and safety need further investigation. This study assessed the changes in health-related quality of life (HRQoL) and adverse events in PTSD patients prescribed CBMPs. This observational cohort study included PTSD patients enrolled on the UK Medical Cannabis Registry for 18 months or longer. Changes in PTSD-specific symptoms (IES-R), anxiety (GAD-7), sleep quality (SQS), and general HRQoL (EQ-5D-5 L) were assessed at 1, 3, 6, 12, and 18 months. In 269 patients, significant improvements in PTSD symptoms, anxiety, sleep quality, and HRQoL were observed at all follow-up points (<i>p</i> &lt; 0.001). On multivariate logistic regression, male gender (OR = 0.51; 95% CI:0.28–0.94; <i>p</i> = 0.034) was associated with a reduced chance of reporting improvements in IES-R. Adverse events were reported by 70 (26.02%) patients, with insomnia (<i>n</i> = 42, 15.61%) and fatigue (<i>n</i> = 40, 14.87%) being the most common. CBMPs were associated with improvements in PTSD symptoms, anxiety, sleep, and HRQoL at up to 18 months. Although the study’s observational nature limits causal conclusions, these findings support further assessment of medical cannabis. This is an observational study and is not registered as a clinical trial.